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Background: Proper expression and functioning of transcription factors (TFs) are essential for regulation of different
traits and thus could be crucial for the development of complex diseases. Subjects with Down syndrome (DS) have
a higher incidence of acute lymphoblastic leukemia (ALL) while solid tumors, like breast cancer (BC) and oral cancer
(OC), show rare incidences. Triplication of the human chromosome 21 in DS is associated with altered genetic
dosage of different TFs. V-ets erythroblastosis virus E26 oncogene homolog 2 (ETS2) and Single Minded 2 (SIM2) are
two such TFs that regulate several downstream genes involved in developmental and neurological pathways. Here
we studied functional genetic polymorphisms (fSNP) in ETS2 and SIM2 encoding genes in a group of patients and
control subjects to better understand association of these variants with DS phenotypes.
Methods: We employed an in silico approach to identify potential target pathways of ETS2 and SIM2. fSNPs in
genes encoding for these two TFs were identified using available databases. Selected sites were genotyped in
individuals with DS, their parents, ALL, BC, OC as well as ethnically matched control individuals. We further analyzed
these data by population-based statistical methods.
Results: Allelic/genotypic association analysis showed significant (P < 0.03) differences of rs2070530, rs1051476,
rs11254, rs711 for DS subjects compared to control. rs711 also exhibited significantly different genotypic distribution
pattern in parents of DS probands (P < 0.02) and BC patients (P < 0.02). Interaction analysis revealed independent
main effect of rs711 in all the groups, while rs11254 exhibited independent main effect in DS subjects only. High
entropy values were noticed for rs461155 in the solid tumor groups. Significant interactive effects of rs2070531 with
rs1051475, rs1051476, rs11254 were observed in all the groups except DS.
Conclusions: We infer from the present investigation that the difference in frequencies of fSNPs and their
independent as well as interactive effects may be the cause for altered expression of SIM2 and ETS2 in DS and
malignant groups, which affects different downstream biological pathways. Thus, altered expression of SIM2 and
ETS2 could be one of the reasons for variable occurrence of different malignant conditions in DS.
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Transcription factors (TFs) regulate pathways related to
diseases either through their direct action on the target
genes or by controlling downstream pathways. Hence
they are important candidates for investigating etiology
of complex diseases. There are several TF encoding genes
in the human 21st chromosome (HSA21) and deregulated
expression of any of these could influence downstream
pathways. Due to trisomy of the HSA21 in Down syn-
drome (DS) (MIM# 190685), genetic overdosage of a
number of TF encoding genes is a distinct possibility. DS
patients are prone to acute leukemia, including acute
lymphoblastic leukemia (ALL), while solid tumors espe-
cially breast cancer (BC) is rare [1]. We hypothesized that
DS related abnormalities like intellectual disability, im-
munological imbalance, hormonal alteration, and predis-
position to childhood acute leukemia could be due to
improper expression and functioning of TFs located
in the HSA21. Because disease association studies
have revealed higher differential expression ratio in
different tissues for the TF genes encoding Single
minded 2 (SIM2) and V-ets erythroblastosis virus E26
oncogene homolog 2 (ETS2) within HSA21 [2], here
we explored the role of these two TFs in DS pheno-
type and related malignancies.
SIM2 is important for normal neuronal development.
SIM2 can heterodimerize with aryl hydrocarbon receptor
nuclear translocator (ARNT) and translocate to the nu-
cleus to transcriptionally regulate gene expression [3]. Ex-
pression of SIM2 mRNA has been detected in fetal brain
regions associated with DS pathology [4]. SIM2 also plays
an important role in carcinogenesis. After entry into a cell,
carcinogenic compounds bind to the cytoplasmic Aryl
hydrocarbon receptor (AhR) and are carried to the nu-
cleus. Ligand-bound AhR together with ARNT [5] bind to
the Xenobiotic Response Element present in the promoter
region of certain genes encoding for oxidative enzymes
[6-8]; transcriptional activation of these enzymes acceler-
ates carcinogen metabolism [9]. SIM2 inhibits AhR/ARNT
dimerization, thereby inhibiting carcinogen metabolism
and promoting carcinogenesis [5,10]. In addition, SIM2 is
the second most consistently over expressed gene in pros-
tate cancer [11] and over expression of the short isoform
of SIM2 (SIM2s) is reported in malignant colon, pan-
creas, and prostate tissues as compared to the corre-
sponding normal tissues [9-11]. SIM2 has further been
proposed to have a breast tumor suppressive activity [12]
and a genome-wide linkage scan identified three putative
breast cancer susceptibility loci, one of which (21q22)
harbors SIM2 [13]. Therefore, SIM2 functions as a
tumour selective marker and drug target in several types
of malignancies [10].
Besides SIM2, ETS2 over expression induces craniofa-
cial defects as well as skeletal anomalies in transgenicmice resembling DS [14]. Increased rate of neuronal
apoptosis [15] and amyloid precursor protein (APP)
gene transactivation are also observed upon ETS2 over
expression [16], which might play an important role in
the early onset of Alzheimer’s disease and neuronal ab-
normalities in DS [16].
ETS2 can act both as a transcriptional activator as well
as a repressor during cellular proliferation, differentiation
and tumorigenesis [17-26]. For instance, cell cycle regu-
lator genes like bcl-xL, c-myc, cyclin D1 and p53 are acti-
vated by ETS2 [27,28], while BRCA1 expression is
repressed in breast cancer tissue [29]. Interestingly, cer-
tain genetic translocations in ETS2 were observed in DS
patients suffering from leukemia [30]. An interaction of
ETS2 and ERG with GATA1 mutations were reported in
DS subjects with acute megakaryoblastic leukemia and
activation of the JAK/STAT pathway, a frequent attribute
of megakaryocytic malignancies, was identified as com-
mon phenomena for this malignant transformation [31].
Given the functional importance of SIM2 and ETS2,
we sought out to investigate alterations in their expres-
sion in disease etiology. Functional single nucleotide
polymorphisms (fSNP) in candidate genes are important
indicators for their association with disease phenotypes.
In the present study, fSNPs of SIM2 and ETS2 were ana-
lyzed for their potential role in Indian individuals suffer-
ing from DS, ALL and solid tumors that includes BC
and oral cancer (OC).
Methods
In Silico analysis to predict pathways regulated by SIM2
and ETS2
We undertook computational methods to determine the
probable pathways regulated by SIM2 and ETS2. The
promoter sequences (from-5000 bp to +1000 bp) were
retrieved from the Eukaryotic promoter database (EPD)
(http://www.epd.isb-sib.ch/) and Transcriptional Regula-
tory Element Database (TRED) (http://rulai.cshl.edu/
TRED). Presence of SIM2 and/or ETS2 binding sites in
the promoter sequences were identified by a Perl based
program “Consensus-Finder”.
We retrieved expression profile of the genes harboring
binding sites for SIM2 and ETS2 in different tissues by
using GNF SymAtlas database (http://symatlas.gnf.org/
SymAtlas/). Tissue-specific differential expression pattern
(fold change) were calculated separately by comparing the
median value of expression; value greater than the median
was considered as over expression and value less than me-
dian was considered as under expression. We then deter-
mined co-expression of putative target genes at the site of
over expression/under expression of SIM2 and ETS2 and
promoter sites of these genes were analyzed by GENEDOC
and Promoter Scan tools respectively (http://www-bimas.
cit.nih.gov/molbio/proscan/). Functions of these putative
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logical pathways was analyzed by Panther (http://www.
pantherdb.org/pathway/) and KEGG pathway (http://www.
genome.ad.jp/kegg/pathway.html). The entire process is
presented schematically in Figure 1.
In silico identification of functional variants
We used different web based tools namely SIFT (http://
sift.jcvi.org), PolyPhen (http://coot.embl.de/PolyPhen/),
SNPs3D (http://www.snps3d.org/), Pupasuite 2 (http://
pupasuite.bioinfo.cipf.es), GlobPlot, FastSNP (http://fastsnp.
ibms.sinica.edu.tw), SNP@Promoter (http://variome.kobic.
re.kr/SNPatPromoter), and dbSMR (http://miracle.igib.res.
in/dbSMR) to identify fSNPs in the genomic regions of
SIM2 and ETS2 as reported earlier [32]. fSNPs selected for
genotyping in the present study are listed in Table 1.Genes probably positively 
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Figure 1 Schematic presentation of the in silico methods used for ideSubjects
Five ethnically matched groups of individuals were
recruited for analysis of fSNPs. Healthy volunteers, with-
out any clinical history of intellectual disability or malig-
nant disorder, were recruited as controls (N = 149).
Nuclear families having child with DS (N = 132) were
recruited from the outpatient department of Manovikas
Kendra, Kolkata and trisomic status of the probands was
confirmed by karyotyping. ALL patients (N = 38) were
recruited from the Netaji Subhash Chandra Bose
Cancer Research Institute, Kolkata. Genomic DNA
from post-operative normal tissue, adjacent to malig-
nant BC (N = 49) and OC (N = 54) were collected
from Chittaranjan National Cancer Research Institute
and Indian Institute of Chemical Biology, Kolkata re-
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Table 1 Details on SIM2 and ETS2 functional SNPs explored in this study
Gene SNP ID Position and typea Alleles (A1/A2)b Probable functionc MAF (A2) in other populations
(CEU, HCB, JPT and YRI)d
SIM2 rs2269188 Intronic, regulatory G/C AhR binding site 0.305, 0.567, 0.534, 0.092
rs2070650 Intronic C/A C-Myc binding site 0.358,0.578, 0.456, 0.500
rs79727992 Intronic G/A NK 0.014 (CEU)
rs16994404 Syn, Cod C/T SR protein mediated splicing regulation 100% C (all populations)
rs77335240 Intronic A/C NK No population data
rs78455239 Intronic C/A NK No population data
rs79022672 Intronic G/A NK 0.020 (YRI)
ETS2 rs34373350 NS, cod C/T Damaging 0.006 (CEU), 0.025 (YRI)
rs11700777 Syn, Cod A/G SR protein mediated splicing regulation No population data
rs114481523 NS, cod A/G NK 0.005 (YRI)
rs73450556 Intronic G/T AML-1a banding site 0.500 (YRI)
rs77688599 Intronic G/A NK 0.056 (CEU)
rs60277131 Intronic A/G NK 0.180 (YRI)
rs78391361 NS, cod C/T NK 0.042 (CEU)
rs1803557 NS, cod A/T Damaging No population data
rs34472454 FS, Cod -/C NK No population data
rs113798497 Syn, Cod A/G NK No population data
rs374575 Intronic C/T Transcriptional regulation 0.290, 0.140, 0.041, 0.005
rs2070529 C/T Cf1, AML-1a binding site 0.168, 0.523, 0.610, 0.270
rs2070530 G/C V-Myb binding site 0.168, 0.523, 0.610, 0.290
rs2070531 C/T NIT2 binding site change 0.398, 0.221, 0.227, 0.288
rs434421 C/T Nkx-2, USF binding No population data
rs8128227 C/A NK 0.014 (CEU)
rs6517481 A/G Ttk 69 binding site 0.361, 0.318 (HCB + JPT), 0.300
rs79863249 C/G NK 0.011 (HCB + JPT)
rs60538921 A/G Lyf-1 banding site No population data
rs7276961 A/G HSF binding site change 0.347, 0.466 (HCB + JPT), 0.300
rs1051475 30UTR T/C Transcriptional regulation 0.347, 0.227 (HCB + JPT), 0.200
rs1051476 C/G SR protein mediated Splicing regulation 0.420, 0.239, 0.209, 0.246
rs72094783 -/GA NK No population data
rs116542090 G/A NK 0.008 (YRI)
rs74551083 A/G NK No population data
rs11540409 A/G NK No population data
rs11254 C/T Alteration of miRNA target site 0.432, 0.233, 0.200, 0.250
rs711 G/A Affects SR protein mediated ESE activity 0.425, 0.200 (HCB + JPT), 0.441
aNS = Nonsynonymous, Syn = Synonymous, Cod = Coding, FS = Frame shift.
bA1 = Major allele, A2 = Minor allele, allele mentioned in bold letter is the ancestral allele.
cNK = Not known.
dCEU: Caucasians from Utah with ancestry from western and northern Europe; YRI: Yoruba from Ibadan, Nigeria; HCB: Han Chinese from Beijing, China and JPT:
Japanese from Tokyo, Japan.
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tional Human Ethical Committee approved the study
protocol.
Sample collection, DNA isolation and genotyping
Peripheral blood (~5 ml) collected from control individuals,
DS probands, their parents and ALL patients was used for
extraction of genomic DNA [33]. Target sequences wereamplified and PCR amplicons were subjected to genotyping
(Table 2).
Statistical analyses
Difference in allelic and genotypic frequency of the stud-
ied fSNPs in different study groups as compared to con-
trol was calculated by simple r x c contingency table
(http://www.physics.csbsju.edu/stats/contingency_NROW_
Table 2 Genotyping procedure for the studied SNPs
Gene SNP ID Primer sequence (50-30) Genotyping procedure
SIM2 rs2269188 F: CTCACCACGAGCTACCTGAA RFLP analysis of PCR product using Bsu36I
R: GACCAGGAGAGGGTTTGGTC
rs2070650 F: CAGTGCCATGGCCTTTTTAGA DNA sequence analysis in ABI prism 3130 Genetic Analyzer using
Big Dye sequencing kit v3.1 followed by analysis using Sequencing
Analysis software v 5.2. Electropherograms obtained were further

































rs11254 F: CCATTCATTCGGAGAAAACG RFLP analysis of PCR product using TaqI
R: AAGGCCACGCAGCTAGTAAA
rs711 F: GCAACGGCACAGCTAATTCT RFLP analysis of PCR product using MspI
R: AAATACAACTGTTAAGGGATTCTGA
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eleven fSNPs of Indian control individuals was also com-
pared with four major populations studied in the HapMap
project [Caucasians from Utah with ancestry from western
and northern Europe (CEU), Han Chinese from Beijing,
China (HCB) and Japanese from Tokyo, Japan (JPT) and
Yoruba from Ibadan, Nigeria (YRI)]. Allelic odds ratios
were calculated by Odds ratio calculator (http://www.
hutchon.net/ConfidORnulhypo.htm). All P values obtainedby allelic and genotypic association test were corrected for
multiple testing by PLINK [34] and R program [http://
www.r-project.org/]. Linkage Disequilibrium (LD) between
the SNPs was measured by Haploview 4.1 using default
settings. Haplotype frequency of fSNPs was inspected by
Unphased program (Version 2.404) [35]. Interaction
among the genotypes of SIM2 and ETS2 was analyzed by
multifactor dimensionality reduction (MDR) software
(version 2.0 beta 8.1) [36] and values were expressed as
Table 3 Target genes of SIM2/ETS2 and their probable function identified by in silico analysis
Gene IDs Location Function (Obtained using Panther Pathway tool)
A4GALT 22q13.2 Carbohydrate metabolic process, lipid metabolic process, protein metabolic process
ABCB8 7q36.1 Immune system process, extracellular transport, carbohydrate metabolic process, response to toxin
ABP1 7q36.1 Oxidoreductase activity, immune system process, cellular amino acid and derivative metabolic process
ATP1A1 1p13.1 Hydrolase activity, cation transmembrane transporter activity, ion channel activity, cation transport, lipid transport, lipid
metabolic process, cellular calcium ion homeostasis
ATP1A4 1q23.2 Cation transport, lipid transport, lipid metabolic process, homeostasis
C1QL1 17q21.31 Complement activation, carbohydrate transport, signal transduction, cell-cell signaling, cell adhesion, carbohydrate metabolic
process, lipid metabolic process, cellular component morphogenesis, mesoderm development, skeletal system development,
response to stimulus
C4BPA 1q32.2 Complement activation, signal transduction, cell-cell adhesion, protein metabolic process, blood coagulation
C4BPB 1q32.2 Complement activation, signal transduction, cell-cell adhesion, protein metabolic process, blood coagulation
CEACAM1 19q13.2 Signal transduction, cell-cell adhesion
CYB561 17q23.3 Oxidoreductase activity, respiratory electron transport chain
EMCN 4q24 Cell adhesion
EXOSC2 9q34.12 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
FVT1 18q21.3 Oxidoreductase activity, metabolic process
FXYD5 19q13.12 Ion channel activity, protein binding ion transport, signal transduction
GATA3 10p14 Hydrolase activity, acting on ester bonds, DNA binding, transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process, endoderm development, heart development, hemopoiesis
GNB2L1 5q35.3 Intracellular protein transport, signal transduction
GTF3C5 9q34.2 DNA binding, nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
H1F0 22q13.1 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, organelle organization, establishment or maintenance
of chromatin architecture
HLA-DOA 6p21.32 Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II, cellular defense response
HPD 12q24.31 Cellular amino acid and derivative metabolic process
HRB2 12q21.2 RNA binding, nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
KDELR2 7p22.1 Intracellular protein transport, exocytosis
KLK8 19q13.41 Spermatogenesis, immune system process, cell cycle, protein metabolic process, cell cycle, ectoderm development, nervous
system development, blood coagulation
KRT16 17q21.2 Structural constituent of cytoskeleton, ectoderm development, cellular component morphogenesis
LCK 1p35.1 Female gamete generation, immune system process, carbohydrate transport, apoptosis, cell cycle, cell surface receptor linked
signal transduction, intracellular signaling cascade, carbohydrate metabolic process, protein metabolic process, cell motion,
signal transduction, cell-cell signaling, cell-cell adhesion, ectoderm development, mesoderm development, embryonic
development, angiogenesis, nervous system development, response to stress
LDLR 19p13.2 female gamete generation, cell adhesion
LPPR4 1p21.2 Cell surface receptor linked signal transduction, phosphate metabolic process, lipid metabolic process, signal transduction
MAG 19q13.12 Receptor activity, structural constituent of myelin sheath, receptor binding, B cell mediated immunity, cell surface receptor
linked signal transduction, cell-cell adhesion, signal transduction, cell-cell adhesion, ectoderm development, nervous system
development, response to stimulus
MAGEA3 Xq28 Gamete generation, induction of apoptosis, cell adhesion
MAGEE1 Xq13.3 Gamete generation, induction of apoptosis, cell adhesion
MASP1 3q27.3 Complement activation, protein metabolic process, response to stimulus
MLX 17q21.2 DNA binding, nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, transcription factor activity
MOGAT1 2q36.1 Acyl-CoA metabolic process, lipid metabolic process
MRPL37 1p32.3 Protein metabolic process
MRPS12 19q13.2 Protein metabolic process
NAT5 20p11.23 Acyltransferase activity, protein metabolic process
NDUFA2 5q31.3 Oxidoreductase activity, oxidative phosphorylation, respiratory electron transport chain
PCSK4 19p13.3 Peptidase activity, cell surface receptor linked signal transduction, cell-matrix adhesion, protein metabolic process, signal
transduction
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Table 3 Target genes of SIM2/ETS2 and their probable function identified by in silico analysis (Continued)
PDE6D 2q37.1 Visual perception, sensory perception, nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
PRSS8 16p11.2 Peptidase activity, spermatogenesis, immune system process, protein metabolic process
RELA 11q13.1 B cell mediated immunity, negative regulation of apoptosis, cell cycle, intracellular signaling cascade, nucleobase, nucleoside,
nucleotide and nucleic acid metabolic process, signal transduction, cellular defense response
RER1 1p36.32 Intracellular protein transport
S100A8 1q21.3 Calcium ion binding, receptor binding, calmodulin binding, immune response, macrophage activation, cell cycle, intracellular
signaling cascade, cell motion, cell cycle, signal transduction, response to stimulus
S100A9 1q21.3 Immune response, macrophage activation, cell cycle, intracellular signaling cascade, cell motion, cell cycle, signal transduction,
response to stimulus
SCARB1 12q24.31 Receptor activity, macrophage activation, lipid transport, apoptosis, signal transduction, cell adhesion, lipid metabolic process,
cellular component morphogenesis
SERPINA1 14q32.13 Protein metabolic process
SFRS1 17q22 RNA splicing factor activity, transesterification mechanism, RNA binding, nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
SLC25A21 14q13.3 Cation transport, phosphate transport, lipid transport, nucleobase, nucleoside, nucleotide and nucleic acid transport,
phosphate metabolic process, nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, lipid metabolic process
SLC7A9 19q13.11 Amino acid transmembrane transporter activity, transmembrane transporter activity amino acid transport, cellular amino acid
and derivative metabolic process
SP1 12q13.13 Immune system process, nucleoside, nucleotide and nucleic acid metabolic process
TGM2 20q11.23 Protein metabolic process
TH 11p15.5 Oxidoreductase activity, signal transduction, cellular amino acid and derivative metabolic process
THBS1 15q14 Receptor binding, enzyme regulator activity, immune system process, blood coagulation
TRFP 6p21.1 Ubiquitin-protein ligase activity
TRRAP 7q22.1 Immune system process, induction of apoptosis, cell cycle, nucleobase, nucleoside, nucleotide and nucleic acid metabolic
process, protein metabolic process, cell cycle, signal transduction, organelle organization, establishment or maintenance of
chromatin architecture, response to stress
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calculated by Piface program [37]. Genotype data of four
fSNPs (rs461155, rs1051425 in ETS2 and rs2073601,
rs2073416 in SIM2) were also included for LD, haplotype
and SNP-SNP interaction analysis. For convenience, tripli-
cate homozygous genotypes were considered as diploid
homozygous genotypes in DS probands while the triplicate
heterozygous genotypes were considered as the diploid
heterozygous genotype for all the calculations to compare
with respective reference diploid groups [32,38].
Results
In Silico analysis to predict pathways regulated by SIM2
and ETS2
Computational expression analysis by GNFSymAtlas
showed that all the splice variants of SIM2 and ETS2
were over expressed in 13 tissues and under expressed
in 12 tissues (Additional file 1: Table S1). Both SIM2 and
ETS2 binding sites were identified in 464 genes by the
‘Consensus-Finder’ program from the eukaryotic pro-
moter database. These putative target genes of SIM2 and
ETS2 were sorted into four groups (Additional file 1:
Table S2). Gene set I contains 71 genes, which showed
over expression in all the tissues where SIM2 and ETS2
were also over expressed. Gene set II comprised of 9
genes, which showed down regulation in all the tissueswhere SIM2 and ETS2 were also down regulated. The
3rd and 4th set of genes exhibited reverse pattern of ex-
pression as compared to SIM2 and ETS2. In addition,
SP1 and AP2 were identified as common TFs for both
SIM2 and ETS2 target genes.
Target pathway identification by Panther and KEGG
(Table 3) indicated genes involved in several pathways,
including ones related to the development of ectoderm
and nervous system (KLK8, LCK, MAG), sensory per-
ception (PDE6D), ionic transport (ATP1A1, ATP1A4,
FXYD5, SLC25A2), signal transduction and cell-cell sig-
naling (C1QL1, C4BPA, C4BPB, CEACAM1, FXYD5,
LCK, GNB2L1), cell adhesion (MAGEA3, MAGEE1,
MAG, LDLR, EMCN, CEACAM1, C4BPB, C4BPA,
C1QL1) and induction of apoptosis (LCK, MAGEA3,
MAGEE1, PRSS8, SCARB1, TRRAP). Genes governing
pathways connected to immunological regulation
included ABCB8, ABP1, KLK8, LCK, MAG, PRSS8,
RELA, S100A9, SP1, THBS1, TRRAP, and HLA-DOA.
Interestingly, genes like KLK8, LCK, RELA, S100A8,
S100A9, TRRAP, and GATA3 are known to have roles
in malignant development.
In silico identification of functional variants
Different in silico tools identified functional genetic var-
iants in SIM2 and ETS2. Among them, thirty five (seven
Table 4 Minor allele frequencies in different populations as compared to the Indian control individuals
SNP ID IND MAF CEU MAF Chi Sq, p HCB MAF Chi Sq, p JPT MAF Chi Sq, p YRI MAF Chi Sq, p
rs2269188 0.348 0.305 0.570, 0.450 0.567 9.74, 0.002 0.534 6.57, 0.010 0.092 19.7, 0.000
rs374575 0.066 0.29 16.4, 0.000 0.14 2.61, 0.106 0.041 0.866, 0.352 0.005 4.69, 0.030
rs2070529 0.407 0.168 14.0, 0.000 0.523 2.43, 0.119 0.61 8.000, 0.005 0.27 4.37, 0.037
rs2070530 0.417 0.168 15.0, 0.000 0.523 2.01, 0.157 0.61 8.000, 0.005 0.29 3.69, 0.055
rs2070531 0.293 0.398 2.20, 0.138 0.221 1.29, 0.256 0.227 0.936, 0.333 0.288 0.00, 1.000
rs6517481 0.293 0.361 0.814. 0.367 0.318 (HCB + JPT) 0.212, 0.645 0.3 0.240E-01, 0.877
rs7276961 0.293 0.347 0.570, 0.450 0.466 (HCB + JPT) 6.88, 0.009 0.3 0.240E-01, 0.877
rs1051475 0.276 0.347 1.14, 0.287 0.227 (HCB + JPT) 0.658, 0.417 0.2 1.75, 0.185
rs1051476 0.276 0.42 4.31, 0.038 0.239 0.416, 0.519 0.209 1.32, 0.25 0.246 0.231, 0.631
rs11254 0.28 0.432 4.91, 0.027 0.233 0.658, 0.417 0.2 1.75, 0.185 0.25 0.231, 0.631
rs711 0.26 0.425 6.39, 0.011 0.2 (HCB + JPT) 1.02, 0.313 0.441 7.12, 0.008
MAF: Minor Allele Frequency; CEU: Caucasian population; HCB: Chinese from Beijing, China; JPT: Japanese from Tokyo, Japan; YRI: Yoruba from Ibadan, Nigeria.
Chatterjee et al. BMC Medical Genetics 2013, 14:12 Page 8 of 17
http://www.biomedcentral.com/1471-2350/14/12in SIM2 and twenty eight in ETS2) SNPs were geno-
typed in this study. Functional significance of the SNPs
is indicated in Table 1.Allelic and genotypic frequency distribution
Comparative analysis of MAF in different populations
revealed significant difference in many SNPs (rs374575,
rs2070529, rs2070530, rs1051476, rs11254 and rs711 in
CEU; rs2269188 and rs7276961 in HCB; rs2269188,
rs2070529 and rs2070530 in JPT; rs2269188, rs374575,
rs2070529 and rs711 in YRI) (Table 4). Among seven SNPs
studied in SIM2 (Table 1), only rs2269188 was polymorphic
in the studied population. This SNP showed significant dif-
ference in allelic (χ2 =6.333, P = 0.012, Power = 82.3%) and
genotypic (χ2 =6.41, P = 0.041, Power = 74.17%) frequency
only in ALL compared to the control (Additional file 1:
Table S3). However, the differences were not significant
after correction for multiple testing.
Twenty eight SNPs in ETS2 genomic region were ana-
lyzed and ten of them were polymorphic in the studiedTable 5 SNPs exhibiting significant differences in allelic and g
Group
SNP ID (A1/A2) C P BFP
Father of DS proband (N = 91) rs711 (G/A) 0.019 0.209
Mother of DS proband (N = 118) rs711 (G/A) 0.00198 0.02178
DS proband (N = 132) rs2070530 (C/G) 0.892 1
rs1051475 (T/C) 0.314 1
rs1051476 (C/G) 0.231 1
rs11254 (C/T) 0.04712 0.51832
rs711 (G/A) 0.00352 0.03872
ALL (N = 38) rs2269188 (G/C) 0.01185 0.13035
rs711 (G/A) 0.00895 0.09845
BC (N = 49) rs711 (G/A) 0.00165 0.01815
OC (N = 54) rs711 (G/A) 0.04993 0.54923
BFP = Bonferroni P value, BHP = Benjamini-Hochberg P value, CP = Crude P value, Cpopulation. Eight of the ten ETS2 SNPs (rs374575,
rs2070529, rs2070530, rs2070531, rs6517481, rs7276961,
rs1051475 and rs1051476) did not show any significant
difference in allelic frequency in DS probands, their par-
ent and malignant groups (Additional file 1: Table S3).
rs11254 showed a marginal allelic association in DS pro-
bands (P = 0.04712) which failed to stand Bonferroni
(BF) and Benjamini-Hochberg (BH) correction for multiple
testing (Table 5). rs711 showed significant increase in the
‘G’ allele frequency in probands with DS (χ2 =8.51, BF P
and BH P =0.03, Power = 43.47%) as compared to controls.
Although a significant increase in the ‘G’ allele (χ2 =6.83,
P = 0.00895, Power = 85.03%, OR = 2.6) was noticed in
ALL patients, it was found to be marginally significant after
correction for multiple testing (BH P = 0.06). On the other
hand, a significant increase in the ‘A’ allele (χ2 =9.91, BF P
and BH P =0.01, Power = 88.26%) was observed in BC
patients (Table 5).
Significant differences in genotypic frequency for rs11254
(χ2 = 85.4, P = 0.0001, Power = 99.96%), rs2070530 (χ2 =enotypic distribution
Allelic association Genotypic association
BHP OR (CI) for A1 OR (CI) for A2 C P BFP BHP
0.215 0.622 (0.417-0.928) 1.608 (1.078-2.398) 0.002 0.022 0.022
0.022 0.56 (0.387-0.810) 1.785 (1.234-2.581) 0.001 0.011 0.011
0.892 1.024 (0.729-1.438) 0.977 (0.695-1.372) 0.003 0.033 0.015
0.576 0.829 (0.576-1.194) 1.206 (0.837-1.736) 0.026 0.286 0.057
0.527 0.801 (0.557-1.152) 1.249 (0.868-1.796) 0.014 0.154 0.039
0.259 1.487 (1.004-2.201) 0.673 (0.454-0.996) 0.0001 0.0011 0.001
0.039 1.858 (1.221-2.828) 0.538 (0.354-0.819) 0.004 0.044 0.015
0.065 2.17 (1.175-4.008) 0.461 (0.250-0.851) 0.041 0.451 0.226
0.065 2.617 (1.245-5.501) 0.382 (0.182-0.803) 0.02 0.22 0.220
0.018 0.469 (0.291-0.755) 2.133 (1.324-3.437) 0.002 0.022 0.022
0.549 1.758 (0.995-3.105) 0.569 (0.322-1.005) 0.091 1 0.686
I = 95% Confidence Interval, OR = Odds Ratio.
Table 6 Pair wise LD pattern of studied SNPs
D0 rs6517481 rs7276961 rs1051475 rs1051476 rs2070529 rs2070530 rs2070531 rs461155 rs11254
r2
Control
rs6517481 - 1 0.926 0.926 0.909 0.930 0.949 0.735 0.719
rs7276961 1 - 0.926 0.926 0.909 0.930 0.949 0.735 0.719
rs1051475 0.774 0.774 - 1 0.899 0.923 0.944 0.765 0.722
rs1051476 0.774 0.774 1 - 0.899 0.923 0.944 0.765 0.722
rs2070529 0.499 0.499 0.441 0.441 - 1 0.955 0.836 0.660
rs2070530 0.501 0.501 0.445 0.445 0.958 - 0.977 0.849 0.680
rs2070531 0.902 0.902 0.805 0.805 0.551 0.553 - 0.757 0.718
rs461155 0.366 0.366 0.362 0.362 0.622 0.615 0.389 - 0.612
rs11254 0.491 0.491 0.503 0.503 0.250 0.255 0.490 0.240 -
Father of DS proband
rs6517481 - 1 0.856 0.853 0.871 0.954 0.905 0.907 0.845
rs7276961 1 - 0.856 0.853 0.871 0.954 0.905 0.907 0.845
rs1051475 0.579 0.579 - 1 0.710 0.797 0.888 0.799 0.897
rs1051476 0.560 0.560 0.974 - 0.717 0.802 0.886 0.805 0.931
rs2070529 0.423 0.423 0.369 0.387 - 0.974 0.956 0.807 0.876
rs2070530 0.450 0.450 0.399 0.415 0.841 - 1 0.848 1
rs2070531 0.796 0.796 0.606 0.586 0.494 0.479 - 0.903 0.905
rs461155 0.417 0.417 0.398 0.414 0.579 0.703 0.400 - 0.861
rs11254 0.714 0.714 0.643 0.674 0.442 0.494 0.795 0.376 -
Mother of DS proband
rs6517481 - 1 0.828 0.830 0.919 0.918 0.979 0.769 0.916
rs7276961 1 - 0.828 0.830 0.919 0.918 0.979 0.769 0.916
rs1051475 0.549 0.549 - 1 0.658 0.671 0.849 0.548 0.926
rs1051476 0.563 0.563 0.981 - 0.679 0.693 0.849 0.571 0.927
rs2070529 0.538 0.568 0.346 0.362 - 1 1 0.745 0.918
rs2070530 0.528 0.528 0.346 0.363 0.982 - 1 0.750 0.916
rs2070531 0.920 0.920 0.552 0.565 0.612 0.601 - 0.759 0.937
rs461155 0.370 0.370 0.228 0.243 0.535 0.563 0.346 - 0.728
rs11254 0.823 0.823 0.663 0.677 0.527 0.515 0.861 0.316 -
DS proband
rs6517481 - 1 0.865 0.862 0.875 0.975 0.939 0.761 0.255
rs7276961 1 - 0.865 0.862 0.875 0.975 0.939 0.761 0.255
rs1051475 0.710 0.710 - 1 0.830 0.926 0.903 0.774 0.274
rs1051476 0.680 0.680 0.966 - 0.807 0.903 0.885 0.756 0.266
rs2070529 0.501 0.501 0.476 0.458 - 0.949 0.825 0.812 0.256
rs2070530 0.593 0.593 0.565 0.546 0.859 - 0.911 0.823 0.273
rs2070531 0.754 0.754 0.735 0.718 0.523 0.608 - 0.699 0.269
rs461155 0.375 0.375 0.410 0.404 0.659 0.645 0.376 - 0.167
rs11254 0.039 0.039 0.043 0.039 0.026 0.028 0.037 0.011 -
ALL
rs6517481 - 1 1 1 1 1 1 0.761 1
rs7276961 1 - 1 1 1 1 1 0.761 1
rs1051475 0.939 0.939 - 1 0.926 1 1 0.698 1
rs1051476 0.939 0.939 1 - 0.926 1 1 0.698 1
rs2070529 0.698 0.698 0.638 0.638 - 1 0.926 0.748 0.858
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Table 6 Pair wise LD pattern of studied SNPs (Continued)
rs2070530 0.625 0.625 0.665 0.665 0.894 - 1 0.731 1
rs2070531 0.939 0.939 1 1 0.638 0.665 - 0.698 1
rs461155 0.428 0.428 0.383 0.383 0.529 0.451 0.383 - 0.636
rs11254 0.883 0.883 0.940 0.940 0.582 0.708 0.940 0.339 -
BC
rs6517481 - 1 0.884 0.884 1 1 1 0.5 0.122
rs7276961 1 - 0.884 0.884 1 1 1 0.5 0.122
rs1051475 0.741 0.741 - 1 1 1 0.884 0.891 0.077
rs1051476 0.741 0.741 1 - 1 1 0.884 0.891 0.077
rs2070529 0.631 0.631 0.605 0.605 - 1 1 0.495 0.274
rs2070530 0.605 0.60 0.582 0.582 1 - 1 0.495 0.269
rs2070531 1 1 0.741 0.741 0.631 0.605 - 0.5 0.122
rs461155 0.125 0.125 0.350 0.350 0.204 0.204 0.125 - 0.425
rs11254 0.013 0.013 0.001 0.001 0.041 0.038 0.013 0.088 -
OC
rs6517481 - 1 0.948 0.948 1 1 1 0.334 0.899
rs7276961 1 - 0.948 0.948 1 1 1 0.334 0.899
rs1051475 0.697 0.697 - 1 1 1 0.950 0.632 0.907
rs1051476 0.697 0.697 1 - 1 1 0.950 0.632 0.907
rs2070529 0.607 0.607 0.471 0.471 - 1 1 0.391 0.856
rs2070530 0.630 0.630 0.488 0.488 0.963 - 1 0.306 0.861
rs2070531 0.960 0.960 0.728 0.728 0.582 0.605 - 0.306 0.902
rs461155 0.060 0.060 0.168 0.168 0.137 0.049 0.049 - 0.656
rs11254 0.656 0.656 0.787 0.787 0.360 0.378 0.687 0.189 -
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P = 0.026, Power = 30.01%), rs1051476 (χ2 =8.57,
P =0.014, Power =34.5%) and rs711 (χ2 =11.2, P =0.004,
Power =43.74%) were observed in DS probands. The
heterozygous genotype frequency of rs11254 was found
to be 0.000 in DS probands. rs711 also showed signifi-
cant difference in genotype distribution in parents of
probands with DS (Father: χ2 = 12.8, P = 0.002, Power =
65.76%; Mother: χ2 = 14.6, P = 0.001, Power = 59.81%) as
well as in ALL (χ2 = 7.78, P = 0.02, Power = 82.49%) and
BC (χ2 = 12.1, P = 0.002, Power = 89.24%). ‘AA’ genotype
was absent in the ALL and OC groups. Except for
rs1051475 in probands with DS and rs711 in ALL
patients, the remaining SNPs retained the significance
level after BF and BH correction (Table 5).
LD and haplotype analysis
SNP pairs that showed higher LD (high D’ or r2 value) in
at least one combination or different LD patterns in con-
trol and case groups during pair wise analysis by Haplo-
view 4.1 were sorted out. In control individuals and
parents of probands with DS, all the studied SNPs exhib-
ited strong LD (Table 6). In particular, rs6517481-
rs7276961, rs1051475-rs1051476, rs2070529-rs2070530,rs2070531-rs6517481, rs2070531-rs7276961 pairs exhibited
strong LD in other studied groups. Some paired combi-
nations showed different LD pattern in different disease
groups. For instance, rs11254 showed weak LD with all
the sites in DS and BC groups, while rs461155 showed
weak LD in OC. Statistically significant differences in
frequency of several haplotypes were noticed between
test and control groups (Figure 2). Notably the ‘A-C-C-
C-T-C-C-A-A-T-C-C-C-G-G’ haplotype showed signifi-
cant frequency difference in BC, DS proband and their
parents when analyzed by Unphased. However, compari-
son by simple Chi-square test followed by analysis of
the power of association by Piface (Additional file 1:
Table S4) showed statistically significant difference only
for the DS probands and BC groups (p value 0.054 and
0.013 respectively).
Analysis of gene-gene interaction
Gene-gene interaction analysis by MDR 2.0 beta 8.1 indi-
cated that different combinations of SNPs were interacting
with each other in different ways within these groups. No
highly synergistic interaction was observed in DS pro-
bands, while individual effect of different SNPs were found
to be high in DS [rs2073601 (1.92%), rs461155 (2.64%),
Figure 2 Haplotypes showing significantly different frequency in Father of probands with DS-DSF (A), Mother of probands with DS-
DSM (B), probands with DS- DSP (C), ALL (D), BC (E), OC (F). Order of the SNPs in the haplotypes is rs461155-rs1051425-rs11254-rs374575-
rs2070529-rs2070530-rs2070531-rs6517481-rs7276961-rs1051475-rs1051476-rs2269188-rs2073601-rs2073416-rs711.
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rs2070531 (1.09%), rs6517481 (1.66%), rs7276961 (1.66%),
rs1051475 (2.24%), rs1051476 (2.56%), rs11254 (29.78%)
and rs711 (4.26%)] (Table 7).
While there was no high individual effect of
rs2070529, rs2070530, rs2070531, rs6517481 and
rs7276961, high synergistic interaction of these SNPs
with rs11254 was noticed in mother of probands with
DS (Table 7). In father of probands with DS,
rs2070531, rs6517481 and rs7276961 also made a clus-
ter together with rs2073416. High individual effect of
rs2073601 (1.77%), rs1051475 (2.09%), rs1051476
(2.29%) and rs711 (3.08%) was observed in father of
probands with DS (Table 7), while rs2073601 (1.38%),
rs2073416 (1.96%), rs2269188 (17.17%), rs461155(1.06%), rs1051425 (1.11%), rs374575 (1.10%),
rs1051475 (1.47%), rs1051476 (1.34%) and rs711
(4.03%) showed high individual effect in mothers
(Table 7).
In the malignant groups, rs2070530, rs2070531,
rs6517481, rs7276961, rs1051475, rs1051476 and rs11254
showed synergistic interaction (IG values are mentioned in
Table 8). Many of the studied fSNPs also showed significant
individual effect in ALL [rs2073601 (3.69%), rs2073416
(2.95%), rs2269188 (2.56%), rs374575 (1.03%) and rs711
(3.55%)], BC [rs2073601 (3.50%), rs2073416 (2.17%),
rs461155 (15.15%), rs374575 (4.04%), rs2070529 (3.79%),
rs2070530 (3.03%), rs2070531 (4.01%), rs6517481 (3.88%),
rs7276961 (3.88%), rs1051475 (1.00%), rs1051476 (1.00%),
rs11254 (1.12%) and rs711 (4.56%)] and OC [rs2073601





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Father
rs2073601(1.77) - −0.06 −1.00 −0.72 −1.49 −1.07 −1.22 −0.82 −1.24 −0.99 −0.99 −0.09 −0.08 −1.12 −1.79
rs2073416 (0.94) - −0.65 −0.05 −0.73 −1.12 0.92 −0.37 0.83 −0.46 −0.46 1.41 1.64 0.72 −0.51
rs2269188 (0.22) - 1.10 −0.54 −0.38 0.55 1.32 0.50 0.69 0.69 −0.20 −0.07 0.38 0.12
rs461155 (0.70) - −0.40 0.39 −0.08 −0.11 0.55 −0.19 −0.19 −0.62 −0.54 −0.40 −0.12
rs1051425 (0.38) - −0.58 0.69 −0.18 −0.09 0.55 0.55 0.09 0.19 −0.19 −0.05
rs374575 (0.65) - −0.58 −0.38 −0.85 −0.66 −0.66 −0.87 −0.81 −0.57 −0.42
rs2070529 (0.17) - −0.14 −0.43 −0.18 −0.18 −0.25 −0.18 −0.67 0.06
rs2070530 (0.44) - −0.41 0 0 −0.15 −0.06 1.16 −0.21
rs2070531 (0.49) - −0.41 −0.41 3.43 3.78 2.07 0.37
rs6517481 (0.34) - −0.41 3.21 3.53 0.37 0.04
rs7276961 (0.34) - 3.21 3.53 0.37 0.04
rs1051475 (2.09) - −2.67 −0.69 0.24
rs1051476 (2.29) - −0.66 0.46
rs11254 (0.09) - −0.11
rs711 (3.08) -
Mother
rs2073601 (1.38) - −1.49 −2.99 −0.16 −1.27 −1.38 −0.75 −0.62 −0.14 −0.09 −0.09 −0.67 −0.75 −1.31 −1.40
rs2073416 (1.96) - −4.27 −0.25 −1.45 −1.34 −0.17 −0.17 −0.45 −0.46 −0.46 −0.84 0.03 −0.05 −1.64
rs2269188 (17.17) - −3.97 −3.97 −4.13 −3.25 −2.90 −3.71 −4.19 −4.19 −5.05 −4.92 −3.47 −4.23
rs461155 (1.06) - −0.36 0.19 0.02 0.22 0.44 0.49 0.49 −0.46 −0.53 −0.21 −0.84
rs1051425 (1.11) - −0.95 0.19 −0.25 −1.03 −0.84 −0.84 −0.23 −0.31 −0.84 −0.59
rs374575 (1.10) - −0.75 −0.41 −0.56 −0.66 −0.66 −0.97 −1.03 −0.69 −0.02
rs2070529 (0.63) - −0.54 0.14 0.19 0.19 −0.09 −0.16 2.27 0.66
rs2070530 (0.73) - 0.16 0.3 0.3 0.19 0.07 2.43 0.92
rs2070531(0.36) - −0.47 −0.47 2.8 2.6 5.71 0.52
rs6517481 (0.30) - −0.51 2.07 1.9 2.97 0.73
rs7276961 (0.30) - 2.07 1.9 2.97 0.73
rs1051475 (1.47) - −1.71 −0.72 −1.17
rs1051476 (1.34) - −0.75 −1.04
rs11254 (0.66) - −0.67
rs711 (4.03) -
Probands with DS
rs2073601 (1.92) - −0.37 0.09 −0.34 −0.67 −0.26 −0.81 −0.57 −1.28 −1.14 −1.14 −1.83 −1.74 −3.83 −2.56
rs2073416 (0.26) - 1.10 −0.22 −0.46 0.12 −0.17 −0.41 −0.39 −1.27 −1.27 −0.49 −0.43 −2.17 −1.72
rs2269188 (0.87) - 1.35 −0.92 −0.03 0.56 −0.34 0.94 −0.13 −0.13 −0.39 −0.27 −2.78 −2.46
rs461155 (2.64) - −1.08 0.40 −0.99 −2.07 −0.58 −1.27 −1.27 −1.98 −2.08 −11.9 −3.42
rs1051425 (1.21) - −0.24 −0.84 −1.36 −0.80 −1.69 −1.69 −0.74 −0.62 −2.60 −0.10
rs374575 (0.03) - −0.23 −0.37 0 −0.76 −0.76 −0.48 −0.46 −1.94 −0.47
rs2070529 (1.47) - −1.61 −0.4 −0.96 −0.96 −0.99 −0.88 −8.74 −1.09
rs2070530 (3.04) - −0.77 −1.38 −1.38 −1.7 −1.76 −13.5 −1.98
rs2070531 (1.09) - −1.03 −1.03 −0.8 −0.71 −8.71 −1.31
rs6517481 (1.66) - −2.73 −1.79 −1.71 −5.3 −2.77
rs7276961 (1.66) - −1.79 −1.71 −5.3 −2.77
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Table 7 Individual and interactive effects of SIM2 and ETS2 SNPs in families with DS probands (analyzed by MDR 2.0
beta 8.1) (Continued)
rs1051475 (2.24) - −2.68 −7.08 −2.15
rs1051476 (2.56) - −6.21 −2.47
rs11254 (29.78) - −3.58
rs711(4.26) -
1 = rs2073601, 2 = rs2073416, 3 = rs2269188, 4 = rs461155, 5 = rs1051425, 6 = rs374575, 7 = rs2070529, 8 = rs2070530, 9 = rs2070531, 10 = rs6517481, 11 = rs7276961,
12 = rs1051475, 13 = rs1051476, 14 = rs11254, 15 = rs711 (Entropy values mentioned in bold are in synergistic interaction).
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(1.16%), rs2070531 (1.47%), rs6517481 (1.33%), rs7276961
(1.33%) and rs711 (2.26%)] (Table 8).
Discussion
The present study was aimed at identifying possible in-
volvement of SIM2 and ETS2, two TFs known to have
gene overdosage in probands with DS exhibiting tri-
somy of HSA21. To identify SIM2 and ETS2 targets,
we focused on 464 genes containing binding site for
both these factors in their regulatory regions (−5000 bp
to +1000 bp). Following categorization based on expres-
sion pattern by GNF SymAtlas, 91 genes were identi-
fied as up- or down regulated by these TFs (Additional
file 1: Table S2). Genes like ABP1, HRB2, S100A8,
THBS1, CYB561, GATA1, GATA3, SP1 and AP2 indi-
cated potential activation by SIM2 and ETS2 (gene set
I and II), while genes such as GCNT2, MASP1,
LOC338328, PCSK4, ICAM1, LPPR4, SLC25A21, H1F0
and ATP1A1 indicated potential repression by these
TFs (gene set III and IV). Many of the genes with
binding sites for SIM2 and ETS2, viz. KLK8, LCK,
TRRAP, GATA3, etc. were earlier reported to have role
in neurological as well as malignancy related pathways
[28,39,40]. Analysis in the present study by Panther
also revealed that genes such as KLK8, KRT16, and
LCK carrying binding sites for SIM2 and ETS2, are
involved in the development and function of the
neurological system. Hence over expression of SIM2
and ETS2 might alter expression of the downstream
target genes leading to different DS phenotypes.
Previous analysis of DS revealed ambiguous observa-
tions on expressions of genes in HSA21 and other auto-
somes. For instance, a dosage dependent increase in
transcription across different tissue/cell types was
noticed in DS [41]. Analysis of lymphoblastoid cell lines
generated from unrelated individuals revealed over ex-
pression of several HSA21 genes even in normal healthy
volunteers [42]. In contrast, gene expression profile ana-
lysis of hearts of human fetuses with trisomy of HSA21
showed significant downregulation of 278 genes and
upregulation of 195 genes as compared to controls [43].
On the other hand, serial analysis of gene expression in
lymphocytes from children with DS revealed modest de-
regulation of autosomal genes [44]. Whole genomemicroarray in adult DS brains showed upregulation of
27% of genes on HSA21 as compared to 4.4% of genes
on other autosomes [45]. Contrary to that, microarray
analysis of cultured amniocytes and chorionic villus cells
from fetuses with trisomy 13, 18, or 21 revealed lack of
over expression of most of the HSA21 genes with only
modest changes for genes on all other chromosomes
[46]. It is possible that the differences in gene expression
in HSA21 and other autosomes are due to the tissue of
origin [47].
Differential expression of SIM2 and ETS2 target genes
was also reported in different malignancies. For instance,
the TRRAP gene, involved in transcriptional regulation
and DNA repair, was found to be high in bone metasta-
ses from prostate cancer, intermediate in BC, and low in
lung and kidney cancers [39]. KLK8 was upregulated in
colorectal cancer and ovarian cancer while underex-
pressed in esophageal and cervical cancer [40,48]. Differ-
ential gene expression profiling of approximately 8000
genes in sixty different cancer cell lines revealed differ-
ence in gene expression pattern to be correlated with
the tissue of origin and the physiological properties (e.g.,
doubling time, drug metabolism, and interferon re-
sponse) of cell lines [49]. Difference in expression be-
tween specific cancer cell line and their nonmalignant
counterparts was also noticed [49]. It is intriguing to note
that genes like MAGEA3 and ATP1A1, which indicated
potential over expression in our study, are also over
expressed in leukemia/lymphoma [48,50-52]. However,
THBS1, which also indicated potential upregulation in
the present study, was down regulated in leukemia and
upregulated in lymphoma [48,53]. Thus, it remains un-
clear whether differential expression is also taking place
for genes identified by our present in silico analysis. Fur-
ther validation, involving expression analysis in various
tumor tissues of individuals with DS, will be necessary.
Our next goal was to identify fSNPs in these two TFs.
A number of SNPs with deleterious effects were identi-
fied in both the genes by our in silico approach. Ana-
lysis of allelic frequencies showed significant difference
in MAF for the Indian control population as compared
to other Asian, i.e. Japanese and Chinese, as well as
Caucasian populations. Frequency distribution analysis
revealed that the rs2269188 ‘G’ allele was significantly
high in ALL subjects, which failed to stand test for
Table 8 Individual and interactive effects of SIM2 and ETS2 SNPs in different malignant groups (analyzed by MDR 2.0
beta 8.1)
Interactive effects
SNP ID (individual effect) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ALL
rs2073601 (3.69) - −4.91 −3.23 −1.16 −0.45 −3.42 −1.34 −1.41 −2.55 −2.33 −2.33 −2.45 −2.45 −2.13 −4.27
rs2073416 (2.95) - −1.55 −1.00 −1.97 −2.21 −1.99 −2.25 −2.44 −1.98 −1.98 −2.12 −2.12 −1.58 −3.53
rs2269188 (2.56) - 0.74 −0.29 −0.01 0.79 0.16 −0.47 −0.25 −0.25 −0.22 −0.22 −0.31 −2.15
rs461155 (0.07) - 0.21 −0.53 −0.37 0.30 −0.63 −0.39 −0.39 −0.21 −0.21 −0.29 −0.65
rs1051425 (0.65) - −0.31 −0.13 −0.52 −0.06 0.18 0.18 0.07 0.07 −0.26 −0.74
rs374575 (1.03) - −1.08 −1.18 −1.15 −1.14 −1.14 −0.89 −0.89 −1.06 −0.69
rs2070529 (0.73) - −1.04 −0.91 −0.16 −0.16 0.48 0.48 0.91 −1.15
rs2070530 (0.64) - −1.10 −0.90 −0.90 0.15 0.15 1.87 −1.06
rs2070531 (0.95) - −1.13 −1.13 1.44 1.44 2.53 −1.23
rs6517481 (0.58) - −1.09 2.21 2.21 2.90 −1.00
rs7276961 (0.58) - 2.21 2.21 2.90 −1.00
rs1051475 (0.39) - −0.57 2.52 −0.97
rs1051476 (0.39) - 2.52 −0.97
rs11254 (0.63) - −0.97
rs711 (3.55) -
BC
rs2073601 (3.50) - −4.62 −3.32 −3.69 −3.32 −3.33 −3.89 −3.12 −3.03 −2.66 −2.66 −1.97 −1.97 −0.76 −3.03
rs2073416 (2.17) - −2.10 −2.36 −1.86 −1.78 −4.05 −3.14 2.60 2.47 2.47 1.90 1.90 −0.80 −1.56
rs2269188 (0.92) - −2.70 1.66 0.07 −1.09 −0.14 −2.90 −2.77 −2.77 −0.96 −0.96 −1.45 0.02
rs461155 (15.15) - −0.77 −3.55 −3.99 −3.22 −4.20 −4.07 −4.07 −1.19 −1.19 −1.31 −7.00
rs1051425 (0.58) - −2.71 −1.57 −0.97 −0.97 −1.50 −1.50 0.37 0.37 −0.66 −1.16
rs374575 (4.04) - −5.88 −5.44 −3.83 −4.28 −4.28 −2.39 −2.39 −2.19 −3.01
rs2070529 (3.79) - −5.97 −3.87 −5.35 −5.35 −1.63 −1.63 −0.79 −2.14
rs2070530 (3.03) - −4.90 −5.15 −5.15 −1.54 −1.54 0.33 −1.63
rs2070531 (4.01) - −4.91 −4.91 2.19 2.19 3.81 −2.37
rs6517481 (3.88) - −5.09 0.86 0.86 3.94 −1.95
rs7276961 (3.88) - 0.86 0.86 3.94 −1.95
rs1051475 (1.00) - −1.23 7.32 0.19
rs1051476 (1.00) - 7.32 0.19
rs11254 (1.12) - −1.36
rs711 (4.56) -
OC
rs2073601 (2.04) - −0.91 −1.51 −2.04 −0.62 −1.12 −0.79 −0.79 −1.14 −1.27 −1.27 −1.46 −1.46 −1.38 −2.44
rs2073416 (0.04) - 0.21 −0.41 −0.25 −1.23 0.24 1.00 −0.58 −0.37 −0.37 1.27 1.27 0.42 −1.05
rs2269188 (0.81) - −1.17 0.45 −0.52 −0.49 −0.35 −0.97 −0.94 −0.94 −0.17 −0.17 −0.26 −1.31
rs461155 (13.14) - −0.70 −1.58 −0.64 −0.38 −1.83 −1.69 −1.69 0.38 0.38 −0.47 −1.26
rs1051425 (0.34) - −1.38 −0.77 −0.76 −1.37 −1.07 −1.07 −0.05 −0.05 −0.20 −1.23
rs374575 (1.89) - −2.33 −2.23 −1.45 −1.50 −1.50 −1.56 −1.56 −0.97 −2.66
rs2070529 (1.16) - −1.34 −1.78 −1.47 −1.47 −1.05 −1.05 −0.35 −1.52
rs2070530 (0.91) - −1.68 −1.31 −1.31 −1.92 −1.92 −0.44 −1.63
rs2070531 (1.47) - −2.48 −2.48 1.90 1.90 0.67 −2.13
rs6517481 (1.33) - −2.40 −1.46 −1.46 0.03 −1.99
rs7276961 (1.33) - −1.46 −1.46 0.03 −1.99
rs1051475 (0.48) - −0.69 1.33 −0.73
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Table 8 Individual and interactive effects of SIM2 and ETS2 SNPs in different malignant groups (analyzed by MDR 2.0
beta 8.1) (Continued)
rs1051476 (0.48) - 1.33 −0.73
rs11254 (0.11) - −0.51
rs711 (2.26) -
1 = rs2073601, 2 = rs2073416, 3 = rs2269188, 4 = rs461155, 5 = rs1051425, 6 = rs374575, 7 = rs2070529, 8 = rs2070530, 9 = rs2070531, 10 = rs6517481, 11 = rs7276961,
12 = rs1051475, 13 = rs1051476, 14 = rs11254, 15 = rs711 (Entropy values mentioned in bold are in synergistic interaction).
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ference in ALL, BC and OC groups harbored the
rs2269188 ‘G’ allele. MDR analysis revealed high indi-
vidual effect of this SNP in ALL (2.56%) and in mother
of DS probands (17.17%) but not in any other groups.
‘G’ allele is responsible for AhR binding to SIM2. AhR
binding with ARNT is an important step for carcinogen
metabolism, which is inhibited by SIM2 [6-10]. We
speculate that increased frequency of the rs2269188 ‘G’
allele may result in inappropriate metabolism of car-
cinogenic compounds, thus contributing to the develop-
ment of leukemia.
rs711 is a site for SR protein mediated splicing regula-
tion and may generate splice variants. In the Korean
population, rs711 was reported to be associated with
increased risk for acute myeloid leukemia [54]. In the
present study, difference in allelic frequency for this site
showed a trend to be significant in ALL even after cor-
rection for multiple testing, while DS probands, parents
of DS probands and BC showed significant differences.
MDR analysis supported evidence of individual effect of
this SNP in all the studied groups.
rs11254, rs2070530 and rs1051476 showed significant
difference in genotype distribution in DS probands (BH
P = 0.001, 0.01 and 0.03 respectively). Though there was
individual effect of these SNPs (29.78%, 3.04%, and
2.56% respectively), no significant synergistic effect was
observed. rs11254 showed a very high individual effect
(29.78%) in DS probands which could be due to 100%
reduction in heterozygosity. On the other hand in malig-
nant groups, rs11254 showed interactive effect in syner-
gistic mode with other SNPs (rs2070530, rs2070531,
rs6517481, rs7276961, rs1051475 and rs1051476).
Therefore, this SNP may act differently in DS and other
malignant groups.
While comparing differences in haplotype frequencies
generated by fifteen SNPs, we analyzed each pair by simple
Chi square tests to avoid errors due to multiple compari-
sons. The ‘A-C-C-C-T-C-C-A-A-T-C-C-C-G-G’ haplotype
showed statistically significant higher occurrence in the
control group compared to DS probands and BC. Fre-
quency of this haplotype was also higher compared to
other haplotypes generated from these 15 SNPs, which
may be conferring protection towards the diseases.
MDR analysis exhibited high individual entropy value
for rs461155 in both BC and OC groups. Involvementof risk allele of rs461155 in subjects with these two
solid tumors has also been reported earlier [32]. There-
fore, from the present study we predict that rs461155
may individually play an important role in solid tumor
groups (BC and OC). On the other hand, rs2070530,
rs2070531, rs6517481, rs7276961, rs1051475, rs1051476
and rs11254 may act together in ALL, BC and OC
groups, where rs11254 act as a nodal SNP. In silico
analysis revealed that, rs11254 has a potency to change
miRNA and TF binding sites in the 3'UTR of ETS2.
Presence of risk allele and inappropriate interaction of
rs11254 probably can hamper proper expression of
ETS2. There are various reports on loss of heterozygos-
ity (LOH) of different genes under different malignant
conditions like ovarian tumors [55], BC [56], head and
neck squamous cell carcinoma [57], pituitary tumors
[58], AML [59] etc. We found 100% LOH for rs11254
in DS probands.
Analysis of LD pattern of studied SNPs exhibited that
rs6517481, rs7276961, rs1051475, rs1051476, rs2070529,
rs2070530, rs2070531, rs461155 and rs11254 are in high
LD in the studied population. MDR analysis also pro-
vided evidence of interaction between these SNPs in the
malignant groups and parents of probands with DS and
thus, may suggest combined effect of these fSNPs in the
studied groups.
Similar to the present observation, SNP pairs
rs2070529-rs2070530 were found to be in high LD in
other populations studied in the HapMap; LD data for
other SNP pairs were not available. Both haplotype dis-
tribution pattern and LD between different SNPs were
found to vary in different groups examined in the
present investigation, which could be attributed to the
difference in allelic frequencies. Whether the observed
difference is contributing to the disease etiology requires
further analysis.
Our results do not imply that ETS2 and SIM2 are the
only TFs in the HSA21 with a role in oncogenesis be-
cause several other TFs, located in the HSA21, also have
association with malignancies [31,60]. For example,
increased expression of BACH1 (transcriptional regulator
of megakaryocytic differentiation process) and SON
(homologous sequence with MYC family of oncoproteins)
were reported in association with myeloid leukemia in DS
[61]. RUNX1 and ERG were hypothesized as candidates
for leukemia in non-DS patients; however, triplicate
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transient myeloproliferative leukemia in Ts1Cje mice and
thus, these two genes may not be directly responsible for
development of leukemia in individuals with DS [62]. Fur-
ther analysis of these TFs, in association with SIM2 and
ETS2, would help us to understand their actual role in DS
associated malignancies.
Conclusions
We summarize that, a) the rs2269188 ‘G’ allele, showing
trend for higher occurrence in ALL patients (BH P = 0.06,
OR = 2.6), may play a regulatory role in ALL by altering
carcinogen metabolism; in mother of probands with DS
also, this SNP may contribute some regulatory role as the
individual effect of this SNP calculated by MDR analysis
was very high (Table 7); that b) rs711 may have very im-
portant role in DS and associated malignancies; that c) the
fSNP rs11254 may act as a core SNP in the interaction
cluster of rs6517481, rs7276961, rs1051475, rs1051476,
rs2070529, rs2070530 and rs2070531, thus playing a role in
malignant development in BC, OC, ALL; in parents of DS
probands, these SNPs also showed strong interaction while
in DS, a high individual effect of rs11254 was found; and
that d) rs2070530, rs711 and rs11254 (with 100% LOH)
showed strong genotypic association with DS. This prom-
inent difference in status of fSNPs of SIM2 and ETS2 may
indicate a significantly different pattern of SIM2 and ETS2
regulation in the studied groups, eventually leading to
altered expression of their downstream genes associated
with distinct disease phenotypes.
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